Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Nihon Pharmaceutical Co., Ltd |
---|---|
Information provided by: | Nihon Pharmaceutical Co., Ltd |
ClinicalTrials.gov Identifier: | NCT00745459 |
Patients who require gastric endoscopy, including the patient population* excluded from the phase III controlled clinical study of NPO-11, will receive an intragastric single dose of NPO-11 20 mL. The efficacy of NPO-11 as a premedication for endoscopy will be evaluated based on the percentage of patients having no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy (primary outcome measure). The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions (ADRs) observed between administration and seven days after administration.
Patient population excluded from the phase III controlled clinical study of NPO-11
Condition | Intervention | Phase |
---|---|---|
Stomach Diseases |
Drug: NPO-11 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy (Open-label Study) |
Estimated Enrollment: | 100 |
Study Start Date: | September 2008 |
Study Completion Date: | August 2009 |
Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
N: Experimental
20 mL NPO-11
|
Drug: NPO-11
20 mL NPO-11
|
Ages Eligible for Study: | 20 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Inpatients or outpatients of either sex who meet criteria (1) and (2) below will be enrolled in the study.
Patients have to provide written informed consent for voluntary participation in the study.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the study. The criteria (2) and (3) will be confirmed during endoscopy. Patients who meet any of these criteria will be withdrawn from the study at the time of confirmation.
Responsible Party: | Nihon Pharmaceutical Co., Ltd ( Yasumasa Ogawa ) |
Study ID Numbers: | NPO-11-01/S-01 |
Study First Received: | September 1, 2008 |
Last Updated: | September 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00745459 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Patients undergoing gastric endoscopy |
Digestive System Diseases Stomach Diseases Gastrointestinal Diseases |
Digestive System Diseases Stomach Diseases Gastrointestinal Diseases |